RxDoctor Payments Data

Raymond Mai, DO

Cardiovascular Disease · Jacksonville, FLNPI 1215399456

Payments from drug & device makers

$13,804in general payments, 2019–2025

Across 432 payments — averaging $31.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$2K
  • AOP Health US, LLC$2K
  • Amgen$855
  • AstraZeneca$816
  • Boehringer Ingelheim$801
  • Novartis$800
  • plus $7K from 34 others

What the payments were for

  • Travel & lodging$1,36610%
  • Food & beverage$12,29189%
  • Education$1461%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,804 in reported general payments places this provider in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$367,288
Medicare patients
1,761
Services billed
6,152

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan435$573,494
VyndamaxTafamidis22$481,780
EliquisApixaban376$396,221
JardianceEmpagliflozin279$354,984
FarxigaDapagliflozin Propanediol169$195,521
Repatha SureclickEvolocumab161$114,470
XareltoRivaroxaban47$55,121
NexlizetBempedoic Acid/Ezetimibe50$44,180
BrilintaTicagrelor21$17,483
Rosuvastatin Calcium1,285$16,221
VascepaIcosapent Ethyl16$12,101
Praluent PenAlirocumab15$11,264
Valsartan260$10,185
Metoprolol Succinate461$6,112
Ezetimibe267$5,621

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$642$878,001398 claims
NovartisEntresto$800$573,494435 claims
Boehringer IngelheimJardiance$801$354,984279 claims
AstraZenecaFarxiga, Brilinta$816$213,004190 claims
Johnson & JohnsonXarelto$263$55,12147 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$426$49,39463 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →